Advanced Search

The American Journal of Psychiatry, VOL. 157, No. 11

Book Forum: MOOD DISORDERS | November 01, 2000

Neurochemistry of Schizophrenia and Depression

DANIEL P. VAN KAMMEN, M.D., PH.D.

Am J Psychiatry 2000;157:1901-1901. 10.1176/appi.ajp.157.11.1901

View Article Information

By Aman U. Kahn, M.D. Clovis, Calif., A.J. Publishing, 1998, 366 pp., price not available.

Article

text A A A

It used to be that the major hypotheses of schizophrenia and depression were limited to excess dopamine in schizophrenia and lower levels of noradrenaline and serotonin (and an overactive hypothalamic-pituitary-adrenal [HPA] axis) in depression. It is clear that the decade of the brain has produced a wealth of data. We are no longer studying schizophrenia subtypes with changes in dopamine, γ-aminobutyric acid (GABA), glutamate, opioid, serotonin, or acetylcholine. All these systems may be involved in the pathophysiology of these disorders. The biochemistries of schizophrenia and depression have become so complex that it is hard to make sense out of the data unless we understand the different systems and their interactions. It is hard for the uninitiated to deal with all this without some guidance. Not to mention those of us who spend a lifetime studying the biochemical and clinical aspects of these disorders.

Aman Kahn reviews the literature of the different neurotransmitter systems from acetylcholine to vasopressin, from cholecystokinin to sigma receptors, from a multisystem perspective. He points out the many biochemical differences and similarities between schizophrenia and depression. He takes the reader systematically through the different putative neurotransmitter system hypotheses. Every system is briefly discussed followed by a review of the findings, regardless of whether they are traditional neurotransmitter or neuropeptide systems. What I particularly liked about the book was a discussion of how and with which other systems a given neurotransmitter system interacts and how that potentially affects our present conceptualizations. The author in his review reveals that almost all systems have produced positive findings in both disorders. He also points at promising areas of further research.

For example, although primarily studied in affective disorders, the HPA axis is frequently found to be abnormal in schizophrenia. Plasma HVA, which reflects only 30% or more brain dopamine metabolism, is considered to be a good marker of central dopamine activity. On the other hand, plasma GABA, 95% of which comes from the brain, is highly understudied in both depression and schizophrenia. The limited pursuit of single neurotransmitter systems has not addressed major areas of clinical interest such as the difference between unipolar and bipolar depression.

A book like this cannot be complete. The task of judging all the available literature from the last 25 years and making sense of it or providing new insights is daunting. Although extensive references are in the back of each chapter, it is unavoidable that we miss some of our favorite studies. I hope that second messengers, immune and membrane abnormalities, and mania can be included in the biochemical review of the two disorders in future editions. A minor irritant in an overall well-appreciated book is the many misspellings of names in the text. Fortunately, the references themselves are correct.

Aman Kahn has made an important contribution. While we are waiting for clarification of the genetic underpinnings of these complex disorders and their altered biochemistries, a review like this will have to do. Many would-be and experienced students of the brain will find this a useful book.

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.

Submit a Comments

Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of JBJS editorial staff.

* = Required Field

Comment Author(s)*(if multiple authors, separate names by comma)

Example: John Doe

Affiliation & Institution*

Comment Title*

Comment*

Cancel

Print
E-mail

Recipient(s) will receive an email with a link (good for 72 hours) to 'Neurochemistry of Schizophrenia and Depression' and do not need to have American Journal of Psychiatry account to access the content.
Your Name:*
Example: John Doe

Email Address:* CC Me:
Enter your valid email address. Example: jdoe@example.com

Recipient's Email Address:*
Separate multiple email address with semi-colons (up to 5).

Subject:* 's American Journal of Psychiatry: 'Neurochemistry of Schizophrenia and Depression'
Subject for your email.

Message:
(Optional, message will truncate at 1000 characters)

Processing your request... Please Wait...

Copyright © in the material you requested is held by The American Psychiatric Association (unless otherwise noted). This email ability is provided as a courtesy, and by using it you agree that you are requesting the material solely for personal, non-commercial use, and that it is subject to The American Psychiatric Association's Terms of Use. The information provided in order to email this topic will not be used to send unsolicited email, nor will it be furnished to third parties. Please refer to The American Psychiatric Association's Privacy Policy for further information.

Copyright © American Psychiatric Association. All rights reserved.
Share
Get Citation

DANIEL P. VAN KAMMEN; Neurochemistry of Schizophrenia and Depression. American Journal of Psychiatry. 2000 Nov;157(11):1901-1901.

Download citation file:

RIS (Zotero)

EndNote

BibTex

Medlars

ProCite

RefWorks

Reference Manager

Copyright © American Psychiatric Association. All rights reserved.
Reprints